Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

an anti-VEGF antibody joined to the functional parts of a pair of anti-PD-1 antibodies in early clinical development. Other candidates are also coming through development, including Ottimo Pharma ...

Its solution is a licensing deal with Chinese biotech LaNova Medicines for LM-299, which consists of an anti-VEGF antibody joined to the functional parts of a pair of anti-PD-1 antibodies.

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors ...

Incyte Corp. (INCY) announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz)—a humanized monoclonal antibody targeting PD-1—combined with carboplatin and ...

Under the terms of the royalty purchase agreement, MacroGenics received a $70 million upfront payment for the sale of its ...

Immunotherapy has revolutionized cancer treatment by mobilizing the immune system to attack tumor cells. Major advances, such as immune checkpoint inhibitors (notably against the PD-1 protein), have ...

Pharmacodynamics provides mechanistic validation, demonstrating dose-dependent binding of IW-601 to myeloid cells (monocytes ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 pati ...